Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting

Fonseca, Eduardo; Iglesias, Raquel; Paradela, Sabela; Fernández‐Torres, Rosa; Elberdín, Laida

doi:10.3109/09546634.2014.933166

Cited by 13 publications

(6 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first point of strength of our study consists in having observed a large cohort of patients and having considered all the switches that occurred in the follow-up period. Indeed, many studies in the literature focus on a specific switch, from etanercept to infliximab [ 24 , 27 , 28 ], from etanercept to adalimumab [ 22 , 23 , 29 , 30 ], etc., and are based on data collected in a single hospital; larger studies that consider all switches, from any PSObio drug to any PSObio drug, usually only consider the first switch for each patient [ 31 , 32 ].…”

Section: Discussionmentioning

confidence: 99%

Use of Biological Drugs for Psoriasis: A Drug-Utilization Study Using Tuscan Administrative Databanks

Giometto

Tillati

Baglietto

et al. 2022

IJERPH

View full text Add to dashboard Cite

Our study aims at providing evidence on patterns of use of biologic drugs for psoriasis in Tuscany, Italy. We conducted a drug-utilization study based on administrative databanks of Tuscany (EUPAS45365) from 2011 to 2019. We selected new users of etanercept, infliximab, adalimumab, ustekinumab, or secukinumab between 1 January 2011 and 31 December 2016. We considered subjects with psoriasis and followed subjects until the end of the study period (three years after the first dispensation of biologic drug for psoriasis) or the patient’s death, whichever came first. We censored subjects for pregnancy or neoplasia. For each subject, we defined the state as the weekly coverage of one of the biologic drugs of interest. We then defined the switch as the change from a state to another one. A total of 7062 subjects with a first dispensation of a PSObio drug in the inclusion period was identified, and 1839 (52.9% female, 51.6 mean age) patients were included in the analysis. Among new users of adalimumab (N = 770, 41.9%), one third showed a continuous behaviour whereas the others moved to etanercept and ustekinumab. New users of etanercept (N = 758, 41.2%), had the highest proportion of switchers, with adalimumab most often being the second choice. New users of infliximab (N = 159, 8.6%) experienced the highest proportion of treatment discontinuation. The present study suggests that the majority of patients treated with PSObio drugs do not switch from one active ingredient to another. However, patients who started biological therapy with etanercept had the highest frequency of switching to other PSObio drugs, whereas those who started with secukinumab or ustekinumab had the lowest.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of Biological Drugs for Psoriasis: A Drug-Utilization Study Using Tuscan Administrative Databanks

Giometto

Tillati

Baglietto

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…This may be due to differences in baseline characteristics of the patient populations or in the pre-treatments and statistical analysis applied. A recent study by Fonseca et al 10 addressed the influence of previous etanercept failure on the effectiveness and safety of adalimumab in psoriasis patients in a real-world setting. Authors concluded that previous etanercept failure does not seem to jeopardize the success and safety of subsequent adalimumab treatment.…”

Section: Discussionmentioning

confidence: 99%

Adalimumab in the treatment of moderate‐to‐severe chronic plaque psoriasis in patients switching from other biologics

Sator

Richter

Saxinger

et al. 2015

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Primary failure was defined as an insufficient response (patients not achieving PASI 50) at week 12-16, according to the medication. Secondary failure was defined as the loss of response (PASI [ 50% of initial value) in a patient who had previously achieved PASI 50 response at week 12-16 [8].…”

Section: Methodsmentioning

confidence: 99%

Biologic Therapy for Moderate to Severe Psoriasis. Real-World Follow-up of Patients Who Initiated Biologic Therapy at Least 10 Years Ago

Elberdín

Fernández‐Torres

Paradela

et al. 2022

Dermatol Ther (Heidelb)

Self Cite

View full text Add to dashboard Cite

Introduction:The aim of this study was to evaluate response and drug survival of biologic therapy in patients with moderate to severe plaque-type psoriasis who initiated biologic therapy at least 10 years ago, in a real-world setting. Methods: This was an observational retrospective follow-up study that included patients with moderate to severe plaque-type psoriasis who initiated biologic therapy between October 2006 and December 2009. Efficacy was expressed as the percentage of patients achieving a 50, 75 and 90% reduction from baseline in the Psoriasis Area and Severity Index (PASI 50, PASI 75, PASI 90, respectively) every 3 months during the first year of therapy and then every 12 months up to the end of follow-up or withdrawal from the study. Results: A total of 56 patients were included in the study, representing 140 treatment lines (median 2, range 1-8); of these patients, 53 were still receiving biologic therapy at the end of the study. The mean duration of biologic therapy was 140.4 (range 47.6-175.4) months. Etanercept was used in 98.2% of patients, followed by efalizumab (42.9%), adalimumab (41.1%), ustekinumab (33.9%) and infliximab (16.1%). Treatment lines were switched in 62.1% of treatments: 24.3% due to secondary failure, 20.7% due to primary failure and 3.6% due to side effects. No patient treated with anti-interleukins had to discontinue treatment due to side effects. Ustekinumab had the highest drug survival.Conclusions: This study in the real-world-setting shows maintenance of long-term efficacy and safety of biologic therapy in patients with moderate to severe plaque psoriasis in daily practice who initiated biologic therapy 10 years ago.

show abstract

Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting

Abstract: Previous etanercept failure seems not influence the success and safety of adalimumab treatment in moderate to severe plaque psoriasis.

Cited by 13 publications

References 36 publications

Use of Biological Drugs for Psoriasis: A Drug-Utilization Study Using Tuscan Administrative Databanks

Use of Biological Drugs for Psoriasis: A Drug-Utilization Study Using Tuscan Administrative Databanks

Adalimumab in the treatment of moderate‐to‐severe chronic plaque psoriasis in patients switching from other biologics

Biologic Therapy for Moderate to Severe Psoriasis. Real-World Follow-up of Patients Who Initiated Biologic Therapy at Least 10 Years Ago

Contact Info

Product

Resources

About